Do Early Changes in the HAM-D-17 Anxiety/somatization Factor Items Affect the Treatment Outcome Among Depressed Outpatients? Comparison of Two Controlled Trials of St John's Wort (Hypericum Perforatum) Versus a SSRI

Overview

Journal Int Clin Psychopharmacol

Specialty Pharmacology

Date 2011 Feb 1

PMID 21278577

Citations 4

Authors

Stella Bitran

Amy H Farabaugh

Victoria E Ameral

Rachel A LaRocca

Alisabet J Clain

Maurizio Fava

David Mischoulon

Affiliations

Soon will be listed here.

Abstract

To assess whether early changes in Hamilton Depression Rating Scale-17 anxiety/somatization items predict remission in two controlled studies of Hypericum perforatum (St John's wort) versus selective serotonin reuptake inhibitors for major depressive disorder. The Hypericum Depression Trial Study Group (National Institute of Mental Health) randomized 340 patients to Hypericum, sertraline, or placebo for 8 weeks, whereas the Massachusetts General Hospital study randomized 135 patients to Hypericum, fluoxetine, or placebo for 12 weeks. The investigators examined whether remission was associated with early changes in anxiety/somatization symptoms. In the National Institute of Mental Health study, significant associations were observed between remission and early improvement in the anxiety (psychic) item (sertraline arm), somatic (gastrointestinal item; Hypericum arm), and somatic (general) symptoms (placebo arm). None of the three treatment arms of the Massachusetts General Hospital study showed significant associations between anxiety/somatization symptoms and remission. When both study samples were pooled, we found associations for anxiety (psychic; selective serotonin reuptake inhibitors arm), somatic (gastrointestinal), and hypochondriasis (Hypericum arm), and anxiety (psychic) and somatic (general) symptoms (placebo arm). In the entire sample, remission was associated with the improvement in the anxiety (psychic), somatic (gastrointestinal), and somatic (general) items. The number and the type of anxiety/somatization items associated with remission varied depending on the intervention. Early scrutiny of the Hamilton Depression Rating Scale-17 anxiety/somatization items may help to predict remission of major depressive disorder.

Citing Articles

Early differences in lassitude predicts outcomes in Stanford Neuromodulation Therapy for difficult to treat depression.

Benrimoh D, Azeez A, Batail J, Xiao X, Buchanan D, Bandeira I Npj Ment Health Res. 2024; 3(1):49.

PMID: 39468255 PMC: 11519532. DOI: 10.1038/s44184-024-00099-2.

Predictors of the effectiveness of an early medication change strategy in patients with major depressive disorder.

Dreimuller N, Wagner S, Engel A, Braus D, Roll S, Elsner S BMC Psychiatry. 2019; 19(1):24.

PMID: 30642308 PMC: 6332626. DOI: 10.1186/s12888-019-2014-x.

Fluoxetine versus other types of pharmacotherapy for depression.

Magni L, Purgato M, Gastaldon C, Papola D, Furukawa T, Cipriani A Cochrane Database Syst Rev. 2013; (7):CD004185.

PMID: 24353997 PMC: 11513554. DOI: 10.1002/14651858.CD004185.pub3.

Radioelectric brain stimulation in the treatment of generalized anxiety disorder with comorbid major depression in a psychiatric hospital: a pilot study.

Olivieri E, Vecchiato C, Ignaccolo N, Mannu P, Castagna A, Aravagli L Neuropsychiatr Dis Treat. 2011; 7:449-55.

PMID: 21857785 PMC: 3157488. DOI: 10.2147/NDT.S23420.

References

Fava M, Rush A, Alpert J, Balasubramani G, Wisniewski S, Carmin C . Difference in treatment outcome in outpatients with anxious versus nonanxious depression: a STAR*D report. Am J Psychiatry. 2008; 165(3):342-51. DOI: 10.1176/appi.ajp.2007.06111868. View

Wade A, Schlaepfer T, Andersen H, Kilts C . Clinical milestones predict symptom remission over 6-month and choice of treatment of patients with major depressive disorder (MDD). J Psychiatr Res. 2008; 43(5):568-75. DOI: 10.1016/j.jpsychires.2008.09.008. View

Fava M, Rankin M, Wright E, Alpert J, Nierenberg A, Pava J . Anxiety disorders in major depression. Compr Psychiatry. 2000; 41(2):97-102. DOI: 10.1016/s0010-440x(00)90140-8. View

Davidson J, Gadde K, Fairbank J, Krishnan K, Califf R, Binanay C . Effect of Hypericum perforatum (St John's wort) in major depressive disorder: a randomized controlled trial. JAMA. 2002; 287(14):1807-14. DOI: 10.1001/jama.287.14.1807. View

Bech P . Meta-analysis of placebo-controlled trials with mirtazapine using the core items of the Hamilton Depression Scale as evidence of a pure antidepressive effect in the short-term treatment of major depression. Int J Neuropsychopharmacol. 2002; 4(4):337-45. DOI: 10.1017/S1461145701002565. View

Szegedi A, Muller M, Anghelescu I, Klawe C, Kohnen R, Benkert O . Early improvement under mirtazapine and paroxetine predicts later stable response and remission with high sensitivity in patients with major depression. J Clin Psychiatry. 2003; 64(4):413-20. DOI: 10.4088/jcp.v64n0410. View

Tollefson G, Holman S . How long to onset of antidepressant action: a meta-analysis of patients treated with fluoxetine or placebo. Int Clin Psychopharmacol. 1994; 9(4):245-50. DOI: 10.1097/00004850-199400940-00003. View

Tadic A, Helmreich I, Mergl R, Hautzinger M, Kohnen R, Henkel V . Early improvement is a predictor of treatment outcome in patients with mild major, minor or subsyndromal depression. J Affect Disord. 2009; 120(1-3):86-93. DOI: 10.1016/j.jad.2009.04.014. View

Szegedi A, Jansen W, Van Willigenburg A, van der Meulen E, Stassen H, Thase M . Early improvement in the first 2 weeks as a predictor of treatment outcome in patients with major depressive disorder: a meta-analysis including 6562 patients. J Clin Psychiatry. 2009; 70(3):344-53. DOI: 10.4088/jcp.07m03780. View

10.

Katz M, Meyers A, Prakash A, Gaynor P, Houston J . Early symptom change prediction of remission in depression treatment. Psychopharmacol Bull. 2009; 42(1):94-107. View

11.

McGrath P, Stewart J, Quitkin F, Chen Y, Alpert J, Nierenberg A . Predictors of relapse in a prospective study of fluoxetine treatment of major depression. Am J Psychiatry. 2006; 163(9):1542-8. DOI: 10.1176/ajp.2006.163.9.1542. View

12.

Kilts C, Wade A, Andersen H, Schlaepfer T . Baseline severity of depression predicts antidepressant drug response relative to escitalopram. Expert Opin Pharmacother. 2009; 10(6):927-36. DOI: 10.1517/14656560902849258. View

13.

Stassen H, Delini-Stula A, Angst J . Time course of improvement under antidepressant treatment: a survival-analytical approach. Eur Neuropsychopharmacol. 1993; 3(2):127-35. DOI: 10.1016/0924-977x(93)90264-m. View

14.

Freeman M, Mischoulon D, Tedeschini E, Goodness T, Cohen L, Fava M . Complementary and alternative medicine for major depressive disorder: a meta-analysis of patient characteristics, placebo-response rates, and treatment outcomes relative to standard antidepressants. J Clin Psychiatry. 2010; 71(6):682-8. DOI: 10.4088/JCP.10r05976blu. View

15.

Coryell W, Coppen A, Zeigler V, Biggs J . Early improvement as a predictor of response to amitriptyline and nortriptyline: a comparison of 2 patient samples. Psychol Med. 1982; 12(1):135-9. DOI: 10.1017/s0033291700043385. View

16.

Khan A, Khan S, Walens G, Kolts R, Giller E . Frequency of positive studies among fixed and flexible dose antidepressant clinical trials: an analysis of the food and drug administration summary basis of approval reports. Neuropsychopharmacology. 2003; 28(3):552-7. DOI: 10.1038/sj.npp.1300059. View

17.

Dunner D, Goldstein D, Mallinckrodt C, Lu Y, Detke M . Duloxetine in treatment of anxiety symptoms associated with depression. Depress Anxiety. 2003; 18(2):53-61. DOI: 10.1002/da.10122. View

18.

Linde K, Berner M, Kriston L . St John's wort for major depression. Cochrane Database Syst Rev. 2008; (4):CD000448. PMC: 7032678. DOI: 10.1002/14651858.CD000448.pub3. View

19.

Fava M, Alpert J, Nierenberg A, Mischoulon D, Otto M, Zajecka J . A Double-blind, randomized trial of St John's wort, fluoxetine, and placebo in major depressive disorder. J Clin Psychopharmacol. 2005; 25(5):441-7. DOI: 10.1097/01.jcp.0000178416.60426.29. View

20.

Farabaugh A, Bitran S, Witte J, Alpert J, Chuzi S, Clain A . Anxious depression and early changes in the HAMD-17 anxiety-somatization factor items and antidepressant treatment outcome. Int Clin Psychopharmacol. 2010; 25(4):214-7. PMC: 2909033. DOI: 10.1097/YIC.0b013e328339fbbd. View